Effect of tretinoin nano lipid on acne

Evaluate the efficacy of nano lipid carrier drug delivery system containing tretinoin

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161207031288N2

Enrollment

Registered

2018-01-03

Start date

2017-06-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acne. Acne vulgaris

Interventions

Intervention 1: Intervention group: Administration of tretinoin Nanolipid in Patients with Moderate to Severe Acne. Intervention 2: Control group: Administration of tretinoin Cream in Patients with

Treatment - Surgery

Treatment - Drugs

Intervention group: Administration of tretinoin Nanolipid in Patients with Moderate to Severe Acne

Control group: Administration of tretinoin Cream in Patients with Moderate to Severe Acne

Eligibility

Sex/Gender

All

Age

12 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 12 to 40 years 2. 10 -50 acne lesions 3. No change in diet and life style during the study 4. Signed informed consent voluntarily and knowingly

Exclusion criteria

Exclusion criteria: Long-time exposure to UV radiation History of sensitivity to topical anti acne drug therapy Use of topical anti acne drug therapy including AHA, BHA, benzyl peroxide, vitamin A, retin-A, antibiotics within one month prior to the study Pregnancy / breastfeeding History of systemic antibiotics for acne treatment within one month prior to the study

Design outcomes

Primary

Measure	Time frame
Modified acne severity index. Timepoint: Beforeintervention, one mouthlater ,two mounth after intervention. Method of measurement: MPA580.	—

Secondary

Measure	Time frame
Skin PH. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Skin sebum. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Skin melanin and erythem. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Transepidermal water loss. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Hydration. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Size and value of acne. Timepoint: Before and after 4 and 8 weeks. Method of measurement: Visiopor.	—

Measure

Time frame

Skin PH. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Skin sebum. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Skin melanin and erythem. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Transepidermal water loss. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Hydration. Timepoint: Before and after 4 and 8 weeks. Method of measurement: MPA580.;Size and value of acne. Timepoint: Before and after 4 and 8 weeks. Method of measurement: Visiopor.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaman Ahmad Nasrollahi

Center For Research And Training In Skin Diseases And Leprosy

samannasrol@gmail.com+98 21 8897 7921

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026